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Abstract
Background: Intraperitoneal tumor cell attachment after resection of gastrointestinal cancer may
lead to a developing of peritoneal carcinosis. Intraabdominal application of phospholipids shows a
significant decrease of adhesion formation even in case of rising tumor cell concentration.
Methods: In experiment A 2*106 colonic tumor cells (DHD/K12/Trb) were injected
intraperitonely in female BD-IX-rats. A total of 30 rats were divided into three groups with
treatments of phospholipids at 6% or 9% and the control group. In experiment B a total of 100 rats
were divided into ten groups with treatments of phospholipids at 9% and the control group. A
rising concentration of tumor cells (10,000, 50,000, 100,000, 250,000 and 500,000) were injected
intraperitonely in female BD-IX-rats of the different groups. After 30 days, the extent of peritoneal
carcinosis was determined by measuring the tumor volume, the area of attachment and the
Peritoneal Cancer Index (PCI).
Results: In experiment A, we found a significant reduction (control group: tumor volume: 12.0 ±
4.9 ml; area of tumor adhesion: 2434.4 ± 766 mm2; PCI 28.5 ± 10.0) of peritoneal dissemination
according to all evaluation methods after treatment with phospholipids 6% (tumor volume: 5.2 ±
2.2 ml; area of tumor adhesion: 1106.8 ± 689 mm2; PCI 19.0 ± 5.0) and phospholipids 9% (tumor
volume: 4.0 ± 3.5 ml; area of tumor adhesion: 362.7 ± 339 mm2; PCI 13.8 ± 5.1). In experiment B
we found a significant reduction of tumor volume in all different groups of rising tumor cell
concentration compared to the control. As detected by the area of attachment we found a
significant reduction in the subgroups 1*104, 25*104 and 50*104. The reduction in the other
subgroups shows no significance. The PCI could be reduced significantly in all subgroups apart from
5*104.
Conclusion: In this animal study intraperitoneal application of phospholipids resulted in reduction
of the extent of peritoneal carcinomatosis after intraperitoneal administration of free tumor cells.
This effect was exceptionally noticed when the amount of intraperitoneal tumor cells was limited.
Consequently, intraperitoneal administration of phospholipids might be effective in reducing
peritoneal carcinomatosis after surgery of gastrointestinal tumors in humans.
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Peritoneal carcinosis can be a result of intraperitoneal
tumor cell spread after surgical treatment of colonic can-
cer. Tumor cell attachment occurs through blood-or lym-
phatic vessels or by accidentally opening the colonic
specimen [1]. Serosal invasion of the primary tumor leads
in up to 50% of patients to intraperitoneal metastases [2].
However, even stage 1 and stage 2 of colonic cancer, gas-
tric cancer, uterine cancer or pancreatic cancer may cause
peritoneal dissemination [2]. In gastrointestinal cancer
the detection of free intraperitoneal tumor cells, serves as
an independent prognostic factor [3]. Free floating intra-
peritoneal tumor cells may attach to, degrade and migrate
through the extracellular matrix (ECM) [4]. Particularly if
the peritoneum is damaged and the etracellular matrix is
exposed tumor cell adhesion accumulates [5]. In former
studies we found a widespread peritoneal carcinosis, with
tumor cell adhesion in most peritoneal aeras after intraab-
dominal instillation of tumor cells (Cell line: DHD/K12/
TRb). We could demonstrate that tumor cells predomi-
nantly adhere to injured peritoneal areas. However, the
goal of the underlying study was not locoregional recur-
rence but the effect of phospholipids in the complete peri-
toneal cavity. In addition preliminary studies could show
that a phospholipid emulsion is able to significantly
reduce intraperitoneal tumor cell adhesion [3,6,7].
Phospholipids are natural constituents of peritoneal fluid
secreted by mesothelial cells. These polar phosphoric acid
di-esters are capable to form a lubricant layer on the peri-
toneal surface, which is of paramount importance to pre-
vent adhesion [19,20]. Additionally, treatment with
phospholipids (e.g. gangliosides) affect integrin function,
causing reduced cell motility and adhesion capability after
exogenous addition of phospholipids [8-10]. Further-
more other adhesion-preventing substances are known.
For example Jeekel et al. evaluated the effects of intra-
abdominal treament with Icodextrin, a glucose polymer
solution, in a coloncarcinoma CC531 rat model [11].
As we could demonstrate the positive effect of phospholi-
pids in low dosage in former studies, the aim of the under-
lying experiment was to compare the influence of rising
phospholipid concentrations on the one hand and differ-
ent tumor cell concentrations on the other hand with spe-
cial emphasis on possible side effects.
Methods
Animals and anesthesia
In this study a total of 130 female BD-IX rats (mean body
weight 200 g +/- 10 g) were operated. The animals were
kept under standard laboratory conditions with free
access for food and water entire study, which was per-
formed according to the rules of the "Deusche Tierschut-
zgesetz" (50.203.AC 18, 9/02) and to the guidelines for
the use of laboratory animals. The animals were assigned
to the following groups of 10 rats (Table 1). The surgical
procedure was performed under sterile conditions and
general anesthesia by intramuscular injection of ketamine
(100 mg/kg Bodyweight BW) (Ketamin 10%, Sanofi-Cefa,
Düsseldorf, Germany) and rompun 2% (5 mg/kg BW)
(Rompun 2%, Bayer, Leverkusen, Germany).
Tumor cell culture
Colonic adenocarcinoma induced in syngenic female BD-
IX rats is the source of the cell line (DHD/K12/TRb) used
in this investigation [5]. Cells were obtained from the
European Collection of Animal Cell Cultures (ecacc, Salis-
bury, UK). They were cultivated in monolayers in tissue
culture flasks (75 cm2, Falcon, Becton Dickinson, Heidel-
berg, Germany) in DMEM and Ham's F10 (1:1; GIBCO)
supplemented with 10% fetal bovine serum (GIBCO) and
gentamycin (0,005%; GIBCO). Cells were incubated at
37°C in a humidified atmosphere of 5% CO2. They were
passaged after treatment with 0,125% trypsin for 2 min.
Following centrifugation for 10 min at 200 g, cells were
suspended in 20 ml PBS and pelleted. The cell pellet was
resuspended in 30 ml complete medium and seeded with
a splitting ratio of 1:3. Only cells from three passages were
used for the experiments. On the day of operation 2*106
cells were suspended in 100 µl complete medium for
application for animals in the experimental setting A [5]
(Table 1). In the experimental setting B the cell amount
ranged from 1*104 to 5*105 (Table 2).
Surgical procedure
All animals underwent a laparotomy via midline incision
of 2 cm length. Before closure of the laparotomy wound
tumor cells and either normal saline (controls) or phos-
pholipid solutions with a concentration of either 6% or
9% (Fresenius, Bad Homburg, Germany) were instilled
into the peritoneal cavity.
Experiment A
The animals in experiment A received a constant amount
of 2*106 tumor cells according to our former experiment
[5].
Experiment B
In experiment B different numbers of tumor cells (10,000,
50,000, 100,000, 250,000 and 500,000) were adminis-
tered intraperitoneally with a constant amount of phos-
Table 1: Arrangement of animal groups in experiment A
Experiment A control PL 6% PL 9% period
10 rats 10 rats 10 rats 30 days
(PL = phospholipids)Page 2 of 7
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control group.
Phospholipids
The phospholipid solution consists of phosphatidylcho-
line 70% of the total weight, phosphatidylethanolamine
15% of the total weight, neutral lipids 8% of the total
weight, sphingomyelin < 3% of the total weight and lyso-
phosphatidylcholine < 3% of the total weight.
Evaluation of peritoneal carcinosis
After intervals of 30 days, the animals were sacrificed by
inhalation of a lethal dose of isoflurane. The abdomen
was opened by bilateral paramedian incisions for com-
plete exploration. The extent of peritoneal carcinosis
(mm2) was measured using a digitizer board and calcula-
tion by costum-made software on a personal computer
[12]. After subtle resection, the tumor volume (ml) was
measured by water displacement. Furthermore a modified
peritoneal cancer index (PCI), as described by Sugarbaker
et al. [13], was determined. The original PCI was adapted
concerning tumor size and areas in rats; Tumor size < 2
mm (LS-1); 2.1–5 mm (LS-2), > 5 mm or confluence (LS-
3). Four areas (liver, spleen, colon, and diaphragma) were
added to refine the original PCI because former animal
studies showed metastases in these areas as well and eval-
uation confirmed more detailed information about the
tumor cell dissemination. Therefore the maximum score
was 51 from up to 3*17 areas. Exploration and evaluation
were carried out by an independent, blinded observer
[5,14].
Statistical analysis
All data are expressed as means +/- standard error of the
mean. Statistical analysis was performed by a two-way
ANOVA with pairewise comparison.
Results
Animal experiments
Surgical treatment and injection of phospholpids showed
no side effects. The mean body weight was constant. All
animals developed peritoneal carcinosis during the obser-
vation period. There was no animal that was free of peri-
toneal implants when they were sacrificed. In group 5*104
one animal died before the end of observation period
because of a viral infection.
Experiment A
1. Intraperitoneal tumor volume
The tumor volume in the control group reached 12.0 ± 4.9
ml, in the 6% trial group 5.2 ± 2.2 ml and in the 9% trial
group 4.0 ± 3.5 ml. A significant reduction of tumor vol-
ume was recognized in the 6% trial group (p = 0.001) and
the 9% trial group (p = 0.001) compared to controls. The
difference between 6% and 9% trial group was not signif-
icant (Figure 1).
2. Area of tumor adhesion
The area of tumor adhesion in the control group reached
2434.4 ± 766 mm2, in the 6% trial group 1106.8 ± 689
mm2 and in the 9% trial group 362.7 ± 339 mm2. A signif-
icant reduction of the area of adhesion was assessed in
both trial groups (6%: p = 0.002; 9%: p = 0.001) com-
pared to the control group. The difference between the 6%
and 9% trial group was also significant (p = 0.006) (Figure
2).
3. Peritoneal cancer index
The PCI in the control group reached 28.5 ± 10.0, in the
6% trial group 19.0 ± 5.0 and in the 9% trial group 13.8 ±
5.1. A significant reduction of the PCI was recognized
between the control group and the 6% trial group (p =
0.027) and between the control group and the 9% trial
group (p = 0.001). The difference between 6% and 9%
trial group was also significant (p = 0.048) (Figure 3).
Experiment A: Volume of intraperitoneal tumor (ml, SEM)Figu e 1
Experiment A: Volume of intraperitoneal tumor (ml, 
SEM). (PL6% to control p = 0.001; PL9% to control p = 
0.001; PL6% to PL9% no significance)
Table 2: Arrangement of animal groups in experiment B
Experiment B Control/Tumor 
cell count
PL 9%/Tumor cell 
count
period
10 rats/1*104 10 rats/1*104 30 days
10 rats/5*104 10 rats/5*104
10 rats/1*105 10 rats/1*105
10 rats/2.5*105 10 rats/2.5*105
10 rats/5*105 10 rats/5*105
(PL = phospholipids)Page 3 of 7
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1. Intraperitoneal tumor volume
We found a significant reduction of tumor volume in all
subgroups compared to controls. In the subgroup with the
lowest tumor cell count (1*104) the intraperitoneal
tumor load was marginal with 0.089 ± 0.048 ml in the
treated animals and 0.97 ± 0.26 ml in controls (p <
0.001).
Also in the next subgroup (5*104) we found a significant
reduction of the intraperitoneal tumor volume after treat-
ment with PL 9% (1.47 ± 0.52 ml) compared to the con-
trol group (3.25 ± 1.46 ml) (p = 0.0007). After injection
of 1*105 tumor cells the tumor volume could be halved in
the treatment group (PL 9%: 3.27 ± 1.46 ml; control: 6.77
± 2.47 ml) (p = 0,007).
Looking to group 2.5*105 (control: 8.2 ± 2.62 ml; PL 9%:
4.34 ± 2.86 ml) we also found a significant reduction (p =
0.0031). Even in group 5*105(control: 12.9 ± 2.07 ml; PL
9%: 5.75 ± 2.1 ml) the statistical analysis result in a signif-
icant reduction of tumor volume (p = 0.003) (Figure 4).
2. Area of tumor adhesion
Treatment with PL 9% led to a reduction of tumor adhe-
sion in all subgroups. However, differences were only sig-
nificant in the subgroups 1*104(control: 464 ± 55 mm2;
PL 9%: 65 ± 31 mm2) (p < 0.001), 2.5 * 105 (control:
2693 ± 801 mm2; PL 9%: 1354 ± 884 mm2) (p = 0.0032)
and 5 * 105 (control: 3255 ± 489 mm2; PL 9%: 2151 ± 539
mm2) (p = 0.0013). The differences in the subgroups
5*104 (control: 1254.89 ± 460.31 mm2; PL 9%: 1163.54
± 356.82 mm2) (p = 0.23) and 1*105 (control: 1992.07 ±
710.60 mm2; PL 9%: 1579.33 ± 533.02 mm2) (p = 0.11)
did not reach statistical significance (Figure 5).
3. Peritoneal Cancer Index
The Peritoneal Cancer Index could be reduced in all con-
secutive subgroups. In group 1*104 (control: 7.9 ± 1.7; PL
9%: 2.3 ± 0.6) we found a significant reduction (p <
0.001). In group 5*104 (control: 12.4 ± 3.3; PL 9%: 10.6
± 3.5) the influence of phospholipids was not significant
(p = 0.17). The statistical analysis of group 1*105(control:
19.3 ± 4.8; PL 9%: 10.5 ± 3.9) and 2.5*105(control: 18.7
± 4.6; PL 9%: 9.9 ± 6.2) showed a significant difference (p
< 0.001 and p = 0.0011 respectively). In group 5*105 treat-
ment with PL 9% also resulted in a significant reduction
Experiment B: Volume of intraperitoneal tumor (ml, SEM)Figu e 4
Experiment B: Volume of intraperitoneal tumor (ml, 
SEM). (1*104 p = 0,001; 5*104 p = 0,0007; 1*105 p = 0.007; 
2,5*105 p = 0,0031; 5*105 p = 0,003)
Experiment A: Area of tumor adhesion (mm2, SEM)Figu e 2
Experiment A: Area of tumor adhesion (mm2, SEM). 
(PL6% to control p = 0.002; PL9% to control p = 0.001; PL6% 
to PL9% p = 0.006)
Experiment A: Peritoneal Cancer Index (PCI, SEM)Figu e 3
Experiment A: Peritoneal Cancer Index (PCI, SEM). 
(PL6% to control p = 0.027; PL9% to control p = 0.001; PL6% 
to PL9% p = 0.048)Page 4 of 7
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trol group (22.6 ± 2.9) (p < 0.001) (Figure 6).
Discussion
The invasion of malignant tumor cells is determined by
the capability to migrate, adhere to and degrade ECM
components [15]. This study was focused on the adhesion
of tumor cells and on the preventive influence of phos-
pholipids.
We used an established experimental model of peritoneal
carcinosis after intraabdominal instillation of tumor cells
(Cell line: DHD/K12/TRb) into female BD-IX rats [5,16].
All animals in this experiment developed peritoneal
metastases. The effects could reliably be described by the
area of attachment, the tumor volume and the PCI.
The idea of inhibiting intraperitoneal tumor nidation is
not new. Several intraperitoneal therapies have been
tested. Hagiwara et al. examined the anti-adherent effect
of dextran sulphate after tumor implantation in mice [17].
A prolonged survival in the treatment group after inocula-
tion of melanoma cells was described. Moreover, intraab-
dominal tumor growth of CC531 adenocarcinoma cells in
rats undergoing laparoscopy could be diminished using
low-molecular-weight heparin in combination of intra-
peritoneal lavage und subcutaneous injection [18]. Ogas-
wara et al. [19] have described the inhibition of tumor
invasion and growth testing intraperitoneal applied anti-
oxidants like epigallocatechin gallate (EGCG) in a colon
26-L5 adenocarcinoma mice model. Treating carcinoma-
tosis of colorectal cancer by cytoreduction and hyperther-
mic intraperitoneal chemotherapy have been studied by
Zoetmulder et al. [20]. They calculated the survival after
cytoreduction and perfusing the abdomen with mitomy-
cin C (35 mg/m2) at 40 degrees C to 41 degrees C for 90
minutes. They observed a survival benefit for colorectal
cancer patients with peritoneal carcinomatosis [21].
Regarding angiogenesis as another key step in tumor
growth, invasion and metastasis, antiangiogenic is an
additional approach for antitumor treatment. Thus Nes-
tler et al. [22] have investigated the effect of angiostatin on
the growth of CC531 colon carcinoma cells in vitro and in
a laparoscopic animal model of peritoneal carcinomato-
sis. They found a significantly diminished intraperitoneal
tumor growth in rats after intraperitoneal application of
20 mg angiostatin.
Tumor cells are known to stimulate peritoneal fibrosis,
creating a congenial environment for peritoneal metasta-
sis [10,23]. Phospholipids are capable of forming a
remarkably resistant lubricant layer on the peritoneal sur-
face [24-27]. We suggest that the ability of phospholipids
to cover peritoneal defects with exposed extracellular
matrix subsequently inhibits tumor cell attachment [5].
Intraperitoneal phospholipids have already been used to
prevent postoperative adhesion. They showed a signifi-
cant reduction of adhesion formation [10,25,26]. The
authors found no adverse side effects and no impairment
of healing of anastomosis, laparotomy wounds and liver
incisions after intraabdominal treatment with phospholi-
pids [10,26]. We examined the effect of intraperitoneal
phospholipids in view of the tumor cell adhesion [5]. In
former studies we could reliable demonstrate a significant
reduction of tumor cell adhesion in case of a constant
tumor cell concentration (1*106 tumor cells) [5,14]. With
respect to the idea using phospholipids as an adjuvant
intraperitoneal therapy in case of standard operations we
Experiment B: Peritoneal Cancer Index (PCI, SEM)Figu e 6
Experiment B: Peritoneal Cancer Index (PCI, SEM). 
(1*104 p = 0,001; 5*104 no significance; 1*105 p = 0.007; 
2,5*105 p = 0.001; 5*105 p = 0.0011)
Experiment B: Area of tumor adhesion (mm2, SEM)Figu e 5
Experiment B: Area of tumor adhesion (mm2, SEM). 
(1*104 p = 0,001; 5*104 no significance; 1*105 no significance; 
2,5*105 p = 0,0032; 5*105 p = 0,0013)Page 5 of 7
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concentrations.
In experiment A we could demonstrate a significant reduc-
tion of peritoneal dissemination as measured by all eval-
uation methods after treatment with 6%- and 9%-
phospholipids. In former studies -using the same tumor
cell concentrations but lower phospholipid concentra-
tions (1,5% und 3%)- we found a reduction of peritoneal
dissemination, too. However, the difference between con-
trol-group and treatment-group was not as distinctive as
in this case [5]. In experiment B we diversified the number
of tumor cells to mimic the clinical situation, that during
the resection of a colon cancer only very few tumor cells
were released.
There was a remarkable reduction of peritoneal dissemi-
nation especially in low tumor cell concentrations, sup-
porting our theory of treating every patient with a
gastrointestinal tumor at the end of the operation with
phospholipids to avoid adhesions and peritoneal tumor
dissemination. The absence of statistical significance in
group 5*104 evaluating PCI and "area of tumor adhesion"
possibly can be traced back to a low falling number
because of the dead of an animal in this group. Valuating
the results of the underlaying study we have to stress that
the extent and not the incidence of peritoneal carcinoma-
tosis was reduced. One also has to be aware that our
results derived from a rat model attending only one kind
of gastrointestinal cancer.
This in vivo model of intraperitoneal application of phos-
pholipids to decrease the tumor cell adhesion describes
the effect from a macroscopic and clinical point of view.
Former studies could exclude a cytotoxic effect of the used
phospholipids [25,28,29]. However, various studies
could demonstrate alterations in the adhesive properties
of tumor cells depending on the degree of differentiation
indicating a change of integrin expression [30-33].
According to this further studies are currently in progress
to evaluate the effect of phospholipids on the structure of
cell membranes.
Conclusion
In this experimental animal study, intraperitoneal treat-
ment with phospholipids resulted in reduction of the
extent of peritoneal carcinomatosis after intraperitoneal
administration of free tumor cells. This effect was excep-
tionally noticed when the amount of intraperitoneal
tumor cells was limited. Consequently, intraperitoneal
administration of phospholipids might be effective in
reducing the incidence and extent of peritoneal carcino-
matosis after surgery of gastrointestinal tumors in
humans.
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